#Day one biopharmaceuticals series

Backers included Canaan Partners, Atlas Venture, and Access Biotechnology. Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company.

#Day one biopharmaceuticals series

The company is headquartered in San Francisco, California.ĭay One's distinctive approach, together with their trusted network of pediatric oncology investigators, gives the company an unparalleled ability to advance promising discoveries for patients of any age.ĭay One's first program is DAY101, an oral, once-a-week, type II pan-RAF inhibitor that is currently being evaluated in human clinical trials. The company partners with clinical oncologists, families, and scientists to identify, acquire, and develop emerging cancer treatments that can help both children and adults living with cancer.ĭay One has raised $60M in a Series A round on May 21, 2020. Day One Biopharmaceuticals, Inc NASDAQ: DAWN is a biopharmaceutical company focused on developing and commercializing targeted therapies for patients of all. Jobs At Day One Biopharmaceuticals Senior Executive Assistant, Chief Executive Officer Join Our Research & Development Community Join Our Product Development. The Company is focused on developing and commercializing targeted therapies. Traders who pay close attention to intraday price movement should know that it fluctuated between 13.00 and 13.63. (NASDAQ:DAWN) closed lower on Monday, May 22, closing at 13.27, -0.67 lower than its previous close.

Day One Biopharma is a biotech startup created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer.ĭay One Biopharmaceuticals develops new therapies that change the outcome for people of all ages living with cancer.ĭay One Biopharma was founded in 2018 by Julie Grant and Samuel Blackman. is a clinical-stage biopharmaceutical company. Companies The trading price of Day One Biopharmaceuticals Inc.